ARCT (Arcturus Therapeutics Holdings) EPS (Basic) : $-3.01 (TTM As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings EPS (Basic)?

Arcturus Therapeutics Holdings's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $-1.11. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.01.

Arcturus Therapeutics Holdings's EPS (Diluted) for the three months ended in Dec. 2024 was $-1.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.01.

Arcturus Therapeutics Holdings's EPS without NRI for the three months ended in Dec. 2024 was $-1.12. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -2.99.

During the past 3 years, the average EPS without NRI Growth Rate was 27.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Arcturus Therapeutics Holdings's highest 3-Year average EPS without NRI Growth Rate was 52.70% per year. The lowest was -89.40% per year. And the median was 0.80% per year.

Arcturus Therapeutics Holdings EPS (Basic) Historical Data

The historical data trend for Arcturus Therapeutics Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings EPS (Basic) Chart

Arcturus Therapeutics Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-3.55

-7.74

0.35

-1.12

-3.00

Arcturus Therapeutics Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.32	-1.00	-0.64	-0.26	-1.11

Arcturus Therapeutics Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Arcturus Therapeutics Holdings's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-80.941	-	0)	/	27.000
	=	-3.00

Arcturus Therapeutics Holdings's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-30.005	-	0)	/	27.090
	=	-1.11

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.01

Arcturus Therapeutics Holdings (NAS:ARCT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Arcturus Therapeutics Holdings EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcturus Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121

Website

https://www.arcturusrx.com

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Executives

Pad Chivukula	officer: Chief Scientific Officer & COO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Andy Sassine	officer: Chief Financial Officer	82 DEVONSHIRE STREET, BOSTON MA 02109
Keith C Kummerfeld	officer: See Remarks	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne	director, 10 percent owner, officer: President and CEO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc.	director, 10 percent owner	60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata	officer: Chief Legal Officer	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Steven George Hughes	officer: Chief Development Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow	director	2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes	director	C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949